Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.
Arun Azad, PhD, an associate professor at Peter MacCallum Cancer Centre and the University of Melbourne; fellow at Victorian Cancer Agency; and chair of the ANZUP Cancer Trials Group Translational, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).
The final analysis of the phase 3 PROfound trial, which was presented during the 2020 ESMO Virtual Congress, evaluated the efficacy and safety of olaparib (Lynparza) versus abiraterone acetate (Zytiga) or enzalutamide (Xtandi) in patients with mCRPC who progressed on prior hormonal anticancer treatment and harbored BRCA1/2, ATM, and CDK12 aberrations, says Azad.
Results showed that olaparib significantly improved overall survival compared with enzalutamide or abiraterone.
Moreover, as an early example of the efficacy of precision medicine in men with prostate cancer, these data garnered significant excitement, Azad adds.
As such, several ongoing studies are now evaluating combinations with PARP inhibitors in earlier disease settings, Azad says.
Ultimately, the PROfound study set the stage for precision medicine in the advanced prostate cancer space, Azad concludes.